🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

EndocrinologyICD-10: E10

Find Recruiting Clinical Trials for Type 1 Diabetes

Search T1D trials for beta cell preservation, immune modulation, closed-loop insulin delivery, and hypoglycemia prevention.

🔍 Search Type 1 Diabetes Trials →

About Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system destroys insulin-producing beta cells in the pancreas, resulting in absolute insulin deficiency. It affects approximately 1.5 million Americans and 9 million people globally, with increasing incidence. Unlike type 2 diabetes, T1D is not related to lifestyle and requires lifelong insulin therapy. Management has advanced significantly with continuous glucose monitors (CGM), insulin pumps, and closed-loop systems (artificial pancreas), but immune-mediated beta cell destruction and hypoglycemia risk remain core challenges.

What Types of Type 1 Diabetes Clinical Trials Exist?

T1D clinical trials span immune modulation (teplizumab-based prevention in at-risk individuals, anti-CD3 antibodies, T-regulatory cell therapies), beta cell preservation, closed-loop insulin delivery system optimization, hypoglycemia prevention, islet transplantation, and stem cell-derived beta cell replacement. Prevention trials enroll high-risk individuals (positive for ≥2 islet autoantibodies) before clinical onset. Treatment trials enroll patients with established T1D stratified by disease duration, residual C-peptide, and HbA1c.

Find Recruiting Type 1 Diabetes Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Type 1 Diabetes Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for type 1 diabetes?▾
Recruiting T1D trials include immune modulation studies (teplizumab and successor agents for beta cell preservation), closed-loop insulin delivery (artificial pancreas) system studies, hypoglycemia awareness and prevention trials, islet transplantation protocols, stem cell-derived beta cell replacement studies, and prevention trials for at-risk individuals with autoantibodies but not yet diagnosed.
Are there T1D trials for people not yet diagnosed but at risk?▾
Yes. Screening for T1D autoantibodies (GAD65, IA-2, ZnT8, insulin autoantibodies) can identify individuals in Stage 1 or Stage 2 T1D — at high risk of clinical onset. Teplizumab (FDA-approved for Stage 2 T1D) demonstrated a 2-year delay in clinical onset. Prevention trials enroll first-degree relatives of T1D patients who test positive for multiple autoantibodies.
Does residual C-peptide affect T1D trial eligibility?▾
Yes, for beta cell preservation trials. C-peptide is a marker of residual insulin secretion from surviving beta cells. Trials targeting beta cell preservation require detectable C-peptide — meaning some beta cell function remains. Longer disease duration generally correlates with lower C-peptide. Trials vary by minimum C-peptide threshold and disease duration cutoff.

Related Conditions

Type 2 DiabetesObesityHashimoto's / Autoimmune

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.